*.*.44.54
药智数据企业版
量身打造,体验升级
立即前往
VIP免费试用申请
登录 注册
当前位置: 首页 > 反馈纠错 帮助中心
2-甲氧基丙烯
CAS号 116-11-0
中文别名 甲基异丙烯基醚; 2-甲氧基-1-丙烯; 邻苯二甲酸甲基油酰酯; 2-甲氧基丙烯/甲基异丙烯基醚; 2-甲氧基丙烯, 99%, STAB. WITH CA 0.5% 钾碳酸; 2-甲氧基丙烯, 98%, STAB. WITH CA 0.5% POTASSIUM CARBONATE
英文别名 2-METHOXY-1-PROPENE; ISOPROPENYL METHYL ETHER; Methyl isopropenyl ether; MOP; 1-Propene,2-methoxy-; 2-methoxy-1-propen; 2-methoxy-prop-1-ene; 2-methoxyprop-1-ene; 2-methoxy-propen; CH2=C(CH3)OCH3; Ether, isopropenyl methyl; ether,isopropenylmethyl; 2-METHOXYPROPENE, STAB.; 2-METHYOXYPROPENE; 2-Methoxypropene, stabilized, 98%; 2-METHOXYPROPENE , STABILIZED WITH CA 0.5% POTASSIUM CARBONATE; 2-METHOXYPROPENE, 99.5+%; 2-METHOXYPROPENE:ISOPROPENYL METHYL ETHER 99%; 2-Methoxypropene, 98%, stab. with ca 0.5% potassium carbonate
分子量 72.11
分子式 C4H8O
EINECS编号 204-125-3
综合信息 查看供应
目录导航
提示:点击目录可直接跳转到对应的信息。

物理化学性质

外观性质:无色液体。
溶解性:不溶于水,溶于乙醇、乙醚等。
沸点 :34-36 °C(lit.)
密度 :0.766 g/mL at 20 °C
蒸气压:27.96 psi ( 55 °C)
折射率 :n20/D 1.382(lit.)
闪点 :−21 °F

产品用途

用途一:用作医药中间体
用途二:2-甲氧基丙烯(116-11-0)是合成克拉霉素(Clarithromycin,简称CLM)的中间体。

应用领域






上下游产品信息




化学品安全说明书(MSDS)



储运特性

2-甲氧基丙烯(116-11-0)爆炸极限为8%-31%,应远离火种密闭、阴景地方保存。运输按第3类第2项易燃液体规定办理。



安全术语
S16Keep away from sources of ignition.
远离火源。
S18Handle and open container with care.
小心处理及开启容器。
S33Take precautionary measures against static discharges.
采取措施,预防静电发生。
S9Keep container in a well-ventilated place.
保持容器置于良好通风处。
风险术语
R12Extremely flammable.
极度易燃。
R19May form explosive peroxides.
可能生成爆炸性过氧化物。
R22Harmful if swallowed.
吞食有害。
下游产品
tofogliflozin;tofogliflozin hydrate;DEBERZA;RO-4998452;CSG-452;R-7201;Deberza;Apleway;RG-7201Fostriecin sodium; PD-110161; NSC-339638; CL-1565A; CI-920Intaxel(from Himalayan Yew); Paclitaxel; MPI-5018(with Matrix's anhydrous delivery system); BMS-181339; NSC-125973; Xorane; Genaxol; Pacligel; Paxceed; Genexol; Paxoral(oral formulation); Paxene; Yewtaxan; Anzatax; TaxolIntaxel(from Himalayan Yew); Paclitaxel; MPI-5018(with Matrix's anhydrous delivery system); BMS-181339; NSC-125973; Xorane; Genaxol; Pacligel; Paxceed; Genexol; Paxoral(oral formulation); Paxene; Yewtaxan; Anzatax; TaxolIntaxel(from Himalayan Yew); Paclitaxel; MPI-5018(with Matrix's anhydrous delivery system); BMS-181339; NSC-125973; Xorane; Genaxol; Pacligel; Paxceed; Genexol; Paxoral(oral formulation); Paxene; Yewtaxan; Anzatax; TaxolIntaxel(from Himalayan Yew); Paclitaxel; MPI-5018(with Matrix's anhydrous delivery system); BMS-181339; NSC-125973; Xorane; Genaxol; Pacligel; Paxceed; Genexol; Paxoral(oral formulation); Paxene; Yewtaxan; Anzatax; TaxolColeonol; Boforsin; Colforsin; Forskolin; M-410; L-751362B; HL-362Orlistat; Orlipastat; Tetrahydrolipstatin; R-212; Ro-18-0647/002; Ro-18-0647; XenicalTacrolimus; Fujimycin; L-679934; FK-506; FR-900506; Protopy; Protopic; Prograf(as hydrate)MLS-337; SDZ-MLS-337; SRI-62834(racemate); SDZ-266337Indinavir sulfate; MK-639; L-735524; Crixivan(-)-Epothilone A; Epothilone A(-)-Epothilone A; Epothilone APatupilone; (-)-Epothilone B; Epothilone B; EPO-906Madindoline A; K93-711-A(-)-Desoxyepothilone B; Epothilone D; Desoxyepothilone B; R-1492; KOS-862; dEpoB; NSC-703147L-753037; J-104132BILA-2157; BILA-2157-BSL-732531(-)-Epothilone E; Epothilone EFebrifugineIsofebrifugineNGD-98-1(-)-Desoxyepothilone A; Desoxyepothilone A; Epothilone C; dEpoACelgosivir; MX-3253; MBI-3253; MDL-28574Carisbamate; RWJ-333369; YKP-509